Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03914300 · ClinicalTrials.gov registry record · Phase 2

Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

A Phase 2 study of Poorly Differentiated Thyroid Gland Carcinoma and Thyroid Gland Papillary Carcinoma, sponsored by National Cancer Institute (NCI).

Active
Registry status
Phase 2
Development phase
11
Enrollment target
20
Study locations

NCT03914300 is a Phase 2 study of Poorly Differentiated Thyroid Gland Carcinoma and Thyroid Gland Papillary Carcinoma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 11 participants, below the 31-participant average among 6 other Poorly Differentiated Thyroid Gland Carcinoma trials with a reported enrollment target (65% lower). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03914300, a Phase 2 study of Poorly Differentiated Thyroid Gland Carcinoma and Thyroid Gland Papillary Carcinoma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
11 participants
Enrollment target
20
Study locations

Study Summary

This phase II trial studies how well cabozantinib, nivolumab, and ipilimumab work in treating patients with differentiated thyroid cancer that does not respond to radioactive iodine and that worsened after treatment with a drug targeting the vascular endothelial growth factor receptor (VEGFR), a protein needed to form blood vessels. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab and ipilimumab may work better than the usual approach consisting of chemotherapy with drugs such as doxorubicin, sorafenib, and lenvatinib for this type of thyroid cancer.

Conditions Studied

Poorly Differentiated Thyroid Gland Carcinoma Thyroid Gland Papillary Carcinoma Refractory Thyroid Gland Carcinoma Thyroid Gland Follicular Carcinoma Differentiated Thyroid Gland Carcinoma Refractory Differentiated Thyroid Gland Carcinoma Thyroid Gland Oncocytic Carcinoma Follicular Variant Thyroid Gland Papillary Carcinoma Tall Cell Variant Thyroid Gland Papillary Carcinoma

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Computed Tomography
  • PROCEDURE Magnetic Resonance Imaging
  • DRUG Cabozantinib S-malate
  • BIOLOGICAL Ipilimumab

Study Locations (20)

Kansas

  • University of Kansas Clinical Research Center - Fairway
  • HaysMed - Hays
  • University of Kansas Cancer Center - Kansas City
  • The University of Kansas Cancer Center - Olathe - Olathe
  • University of Kansas Cancer Center-Overland Park - Overland Park
  • Mercy Hospital Pittsburg - Pittsburg
  • Salina Regional Health Center - Salina
  • University of Kansas Health System Saint Francis Campus - Topeka
  • University of Kansas Hospital-Westwood Cancer Center - Westwood

California

  • City of Hope Comprehensive Cancer Center - Duarte
  • Los Angeles General Medical Center - Los Angeles
  • USC / Norris Comprehensive Cancer Center - Los Angeles
  • USC Norris Oncology/Hematology-Newport Beach - Newport Beach

Florida

  • Moffitt Cancer Center-International Plaza - Tampa
  • Moffitt Cancer Center - McKinley Campus - Tampa
  • Moffitt Cancer Center - Tampa

Missouri

  • University Health Truman Medical Center - Kansas City
  • University of Kansas Cancer Center - North - Kansas City

Kentucky

  • University of Kentucky/Markey Cancer Center - Lexington

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 11 participants
Start Date 2020-02-10
Est. Completion 2026-12-17
Phase Phase 2

Sponsor

National Cancer Institute (NCI)

3,257 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03914300

The ClinicalTrials.gov registry entry for NCT03914300 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 31-participant average among 6 other Poorly Differentiated Thyroid Gland Carcinoma trials with a reported enrollment target (65% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 9 conditions, with Poorly Differentiated Thyroid Gland Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT03914300 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Kansas, California, Florida.

Frequently Asked Questions

What is clinical trial NCT03914300 about?

NCT03914300 is a clinical study titled "Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer". This phase II trial studies how well cabozantinib, nivolumab, and ipilimumab work in treating patients with differentiated thyroid cancer that does not respond to radioactive iodine and that worsened after treatment with a drug targeting the vascular endothelial growth factor receptor (VEGFR), a pro...

What is the current status of trial NCT03914300?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2020-02-10. Estimated completion is 2026-12-17.

What conditions does trial NCT03914300 study?

This clinical trial studies the following conditions: Poorly Differentiated Thyroid Gland Carcinoma, Thyroid Gland Papillary Carcinoma, Refractory Thyroid Gland Carcinoma, Thyroid Gland Follicular Carcinoma, Differentiated Thyroid Gland Carcinoma.

What interventions are being tested in trial NCT03914300?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Cabozantinib S-malate (DRUG), Ipilimumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT03914300?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03914300 being conducted?

This trial has 20 study locations across California, Florida, Kansas, Kentucky, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Poorly Differentiated Thyroid Gland Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Poorly Differentiated Thyroid Gland Carcinoma

All registered trials for this condition

Thyroid Gland Papillary Carcinoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.